|
A phosphoinositide 3-kinase inhibitor (PI3K inhibitor) is class of medical drug that functions by inhibiting one or more of the phosphoinositide 3-kinase enzymes, which are part of the PI3K/AKT/mTOR pathway, an important signalling pathway for many cellular functions such as growth control, metabolism and translation initiation. Within this pathway there are many components, inhibition of which may result in tumor suppression.〔Kurtz J.E. Ray-Coquard I., 2012. PI3 kinase inhibitors in the clinic: an update. (). ''Anticancer Research'', 32(7), pp.2463-70〕 These anti-cancer drugs are examples of targeted therapy.〔(【引用サイトリンク】title=PI3K inhibitors: Targeting multiple tumor progression pathways )〕 There are a number of different classes and isoforms of PI3Ks.〔 Class 1 PI3Ks have a catalytic subunit known as p110, with four types (isoforms) - p110 alpha, p110 beta, p110 gamma and p110 delta.〔(Study results provide rationale for use of PI3K inhibitors in therapeutic settings ). News-medical.net. Retrieved on 2010-11-05.〕 The inhibitors being studied inhibit one or more isoforms of the class I PI3Ks.〔 SF1126 is the first PI-3 kinase inhibitor to enter pediatric cancer clinical trials via the NANT consortium. They are being actively investigated for treatment of various cancers.〔(【引用サイトリンク】title=Zeroing in on PI3K Pathway )〕 They are also being considered for inflammatory respiratory disease. ==Notable examples== *Wortmannin an ''irreversible'' inhibitor of PI3K. *demethoxyviridin a derivative of wortmannin. *LY294002〔 a ''reversible'' inhibitor of PI3K. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Phosphoinositide 3-kinase inhibitor」の詳細全文を読む スポンサード リンク
|